Cytochrome P450 17␣-hydroxylase (CYP17) is a single gene-encoded protein with two activities: 17␣-hydroxylase and 17,20-lyase. The two catalytic activities are differentially regulated in health and disease. We took advantage of naturally occurring human mutations to understand the molecular bases of this differential regulation. We identified eight novel mutations in the CYP17 gene, different in nature and spread throughout the gene. As posttranslational modifications appear to be important for activity control, we investigated the phosphorylation state of wild-type and mutant CYP17 proteins. Although phospholabeled protein was seen when the wild-type and most mutant proteins were expressed, no phosphorylation was detected for the F417C mutant. F417C is the only 17,20-lyase deficiency case confirmed at the molecular level and represents the first phosphorylation CYP17-deficient mutant. In search of the physiological agents involved in this process, the effect of cAMP was tested on activity and phosphorylation state of our mutant CYP17 proteins. cAMP stimulates activity and phosphorylation in all cases, except in the F417C and R35L mutants. The lack of response to the physiological second messenger might explain the different phenotypes. The F417C mutant protein, which is already shown to be associated with the lack of electron transfer, provides for the first time a link between the electron transfer system and the phosphorylation state of the CYP17 enzyme in the control of 17,20-lyase activity. (J Clin Endocrinol Metab 85: 1226 -1231, 2000 H UMAN CYP17 is a single microsomal enzyme with two distinct activities: 17␣-hydroxylase, which is necessary for the synthesis of cortisol, and 17,20-lyase, which cleaves the C 17-20 carbon bond, converting C 21 compounds to C 19 steroids dehydroepiandrosterone (DHEA) and androstenedione, the precursors of the sex hormones. Humans have only one gene, CYP17, that encodes only one form of the CYP17 enzyme. Clinical observations have revealed that the two activities are differentially regulated in a tissue-and time-dependent manner, as demonstrated by the distinct steroid secretion pattern in adrenals and gonads and by the adrenarche, the maturation of the adrenal zona reticularis, respectively. Although 17,20-lyase activity can be significantly influenced by the abundance and the interaction with redox partners (1, 2) in different cell types, it seems unlikely that the amount of reducing agents varies substantially in the same cells in a hormonally and developmentally regulated fashion, as observed for 17,20-lyase activity at adrenarche. Posttranslational modifications seem to be a more suitable mechanism for the maturation-dependent regulation of 17,20-lyase activity. Consistent with this hypothesis, Zhang et al (3) demonstrated that phosphorylation of CYP17 is necessary for 17,20-lyase, but not for 17␣-hydroxylase, activity. Nevertheless, the physiological trigger for adrenarche and/or CYP17 phosphorylation remains unknown. The possibility of analyzing patients affected by CYP17 deficiency provides a unique chance not only to clarify the molecular bases of the disease, but also to use a human knockout model to study the influence of cofactors or posttranslational changes on 17␣-hydroxylase and 17,20-lyase activities of CYP17. The same model can be useful to analyze the role of agents that may be involved in the developmental regulation of 17,20-lyase activity in the phosphorylation state and the activity of CYP17.
H UMAN CYP17 is a single microsomal enzyme with two distinct activities: 17␣-hydroxylase, which is necessary for the synthesis of cortisol, and 17,20-lyase, which cleaves the C [17] [18] [19] [20] carbon bond, converting C 21 compounds to C 19 steroids dehydroepiandrosterone (DHEA) and androstenedione, the precursors of the sex hormones. Humans have only one gene, CYP17, that encodes only one form of the CYP17 enzyme. Clinical observations have revealed that the two activities are differentially regulated in a tissue-and time-dependent manner, as demonstrated by the distinct steroid secretion pattern in adrenals and gonads and by the adrenarche, the maturation of the adrenal zona reticularis, respectively. Although 17,20-lyase activity can be significantly influenced by the abundance and the interaction with redox partners (1, 2) in different cell types, it seems unlikely that the amount of reducing agents varies substantially in the same cells in a hormonally and developmentally regulated fashion, as observed for 17,20-lyase activity at adrenarche. Posttranslational modifications seem to be a more suitable mechanism for the maturation-dependent regulation of 17,20-lyase activity. Consistent with this hypothesis, Zhang et al (3) demonstrated that phosphorylation of CYP17 is necessary for 17,20-lyase, but not for 17␣-hydroxylase, activity. Nevertheless, the physiological trigger for adrenarche and/or CYP17 phosphorylation remains unknown. The possibility of analyzing patients affected by CYP17 deficiency provides a unique chance not only to clarify the molecular bases of the disease, but also to use a human knockout model to study the influence of cofactors or posttranslational changes on 17␣-hydroxylase and 17,20-lyase activities of CYP17. The same model can be useful to analyze the role of agents that may be involved in the developmental regulation of 17,20-lyase activity in the phosphorylation state and the activity of CYP17.
We therefore collected a cohort of patients suffering from CYP17 deficiency, analyzed their CYP17 genes for genetic rearrangements, and used them as a model for studying the role of phosphorylation and its control of CYP17 catalytic activities.
Materials and Methods Patients
Ten patients were diagnosed to suffer from CYP17 deficiency. Based on the clinical and biochemical picture, they were divided into two groups: 1) patients suffering from complete combined 17␣-hydroxylase/ 17,20-lyase deficiency (n ϭ 7), and 2) patients affected by isolated 17,20-lyase deficiency (n ϭ 3). Although the diagnosis of complete combined CYP17 deficiency is relatively easy (female infantile external genitalia independent from genetic sex and age; hypertension, hypokalemia, and lack of sexual maturation at the time of expected puberty; lack of response of cortisol, DHEA, and androstenedione to ACTH; and no increase in sex hormones in response to exogenous gonadotropins), the more difficult diagnosis of 17,20-lyase deficiency was made in three genotypically male patients born with ambiguous genitalia on the basis of the known criteria (4) . Briefly, in the presence of intersexual genitalia, a stimulation test with hCG showed no significant response of testosterone, but an increase, or even an exaggerated response of 17-hydroxyprogesterone in the presence of normal cortisol levels. DHEA and androstenedione levels fail to rise under ACTH stimulation.
Mutation analysis
Genomic DNA was extracted from peripheral blood leukocytes (PBL) using the QIAGEN DNA blood and cell culture kit (QIAGEN, Hilden, Germany) and was used to perform PCR exonic amplification and direct sequencing using the dideoxy method applied to thermal cycling as previously described (1) .
Expression studies
To study the functional implications of the mutations found, we established a RT-PCR method using CYP17 messenger ribonucleic acid (RNA) ectopically expressed in PBL of the patients (5). Total RNA was extracted from 500 L whole blood using the RNeasy minikit (QIAGEN). RT was performed on 100 ng total RNA using Superscript reverse transcriptase (Life Technologies, Inc., Grand Island, NY). PCR amplification of CYP17 complementary DNA (cDNA) was performed using the direct primer 5Ј-TCTTGCCTGCCCGCACCCAGCCACC-3Ј and the reverse primer 5Ј-CCCTAACCCCTGGCTGAATGC-3Ј at the following cycling conditions: 93 C for 1 min, 48 C for 2 min, and 68 C for 1 min for 40 cycles. The primers contained an EcoRI and a BamHI restriction site at their 5Ј-ends, respectively, to facilitate subcloning. The mutated cDNAs were subcloned into a pCMV4 vector and transiently transfected into confluent COS-1 cells using 50 g Lipofectamine and 10 g DNA on a 10-cm plate (Life Technologies, Inc.). The correctness of the sequence was proven by sequencing. The transfection efficiency ranged from 30 -50%. Forty-eight hours after transfection, steroidogenic precursors (pregnenolone and progesterone for 17␣-hydroxylase activity and 17-hydroxypregnenolone for 17,20-lyase activity) were added at a concentration of 1 mol/L after suspension in 1 ϫ phosphate buffer. Six hours after its addition, supernatant was removed and kept frozen at Ϫ20 C until measured. To standardize the steroid production, cells were lysed in 1 ϫ PBS, 1.5 mmol/L MgCl 2 , 1 mmol/L ethylenediamine tetraacetate, 1% Triton-X, and 10% glycerol in the presence of protease inhibitors (34 g/mL phenylmethanesulfonylfluoride, 0.7 g/mL pepstatin, and 5 g/mL leupeptin; Roche Molecular Biochemicals), and protein content was measured using Bio-Rad Laboratories, Inc. (Hercules, CA), protein assay reagents. The secreted steroids, i.e. 17-hydroxyprogesterone (17␣-hydroxylase activity) and DHEA (17,20-lyase activity), were measured in duplicate by RIA using Diagnostic Product kits (Los Angeles, CA).
The stimulation experiments were conducted in a similar way, adding 200 mol/L 8-bromo-cAMP (Sigma, Buchs, Switzerland) 2 h before termination of the experiments. The synthesized steroids were assayed as secreted products in the medium, after 6-h incubation, using RIA kits (17-hydroxypregnenolone, ICN Biochemicals, Inc., Costa Mesa, CA; 17-hydroxyprogesterone and DHEA, Diagnostic Products, Los Angeles, CA). All values are expressed as the mean Ϯ sd and represent the results of three independent experiments. S]methionine (100 Ci/mL; NEN Life Science Products, Easytag) for 2 h in methionine-free medium (Life Technologies, Inc.). Labeled cells were lysed in 1 ϫ PBS, 1.5 mmol/L MgCl 2 , 1 mmol/L ethylenediamine tetraacetate, 1% Triton X, and 10% glycerol in the presence of protease inhibitors (34 g/mL phenylmethanesulfonylfluoride, 0.7 g/mL pepstatin, and 5 g/mL leupeptin; Roche Molecular Biochemical) and phosphatase inhibitors for the phosphorylation experiments (100 mmol/L sodium fluoride, 10 mmol/L sodium pyrophosphate, and 2 mmol/L sodium orthovanadate; Sigma). The lysates were clarified by centrifugation at 15,000 ϫ g for 10 min. The supernatants were then bound to protein A-Sepharose (Pharmacia Biotech) preincubated (at least 20 min at room temperature) with anti-human CYP17 antibodies (a gift from Prof. M. Waterman, Nashville, TN) at a dilution of 1:50.000. The cell lysates were incubated on the protein A-Sepharose/antibody complex overnight at 4 C. The immune complexes were then extensively washed and analyzed on 10% SDS-PAGE.
In vivo metabolic labeling and immunoprecipitation
Human NCI-H295R (CRL-2128, American Type Culture Collection, Manassas, VA) adrenocortical carcinoma cell extract was used as a positive control for CYP17 protein.
Results

Complete-combined deficiency
Two related patients of Italian origin affected by complete CYP17 deficiency were found to bear a homozygote 24-bp deletion in exon 1, leading to the predictive loss of eight amino acid residues 70 -77. The mutant protein lost both 17␣-hydroxylase and 17,20-lyase activities, as expected given the severe phenotype.
Intriguingly, analysis of the expressed gene in PBL of the parents, who are obligate heterozygotes, showed only one product corresponding to the wild type, as the deleted product would not be expressed. The RT-PCR analysis of RNA derived from PBL of the affected individuals showed the expected smaller product. When the same analysis was performed on RNA extracted from the gonads of these two patients, only patient 2 had the expected product, whereas patient 1 showed consistently two smaller cDNA products (Fig. 1) .
A second Italian patient affected by the complete form of the disease also carried a homozygote 3-bp deletion with the consequent loss of a glutamate at position 330 (or 331). The mutant protein expressed in COS-1 cells is totally inactive. Another patient was found to carry a homozygote R96W missense mutation that leads to the synthesis of a protein retaining 25% of both activities compared to the wild type. An additional apparently unrelated patient, of Italian origin but currently living in Germany, bears the same rearrangement in the CYP17 gene. This raises the possibility of a founder effect in the Italian population. The last case, a Japanese patient affected by complete-combined deficiency, was a compound heterozygote; one allele bears a 3-bp deletion in exon I with consequent loss of phenylalanine 53, and the other allele carries a 1-bp insertion leading to a frame shift introducing a premature stop codon at position 329 in place of a tyrosine. The expression studies in COS-1 cells demonstrated that the ⌬F53 protein retains 10% 17␣-hydroxylase activity and 13% 17,20-lyase activity, with no significant difference between the two enzymatic activities. This slightly contrasts what was previously observed (6) . In fact, in the previously published work there was a more striking divergence between the two enzymatic activities of CYP17 (20% for 17␣-hydroxylase and 5% for 17,20-lyase compared to wild type). The reason for this discrepancy is at present unclear. The results of the mutation analysis and expression studies are summarized in Table 1 .
17,20-Lyase deficiency
The F417C mutation has been previously described and has been included in this work as the only case of isolated 17,20-lyase deficiency confirmed at the molecular level. The CYP17 gene of a 46,XY Turkish patient with genital ambiguity and undescended testes was found to carry two different mutations in the two alleles. The allele of paternal origin has a G to A transition in exon 8, leading to a R496H missense mutation in the C-terminal region of the protein.
The allele inherited from the mother bears the missense N177D rearrangement due to an A to G transition in exon 3. The expression studies of the mutant proteins demonstrated that the two mutations are responsible for a dramatic reduction of both enzymatic activities, in contrast to the clinical phenotype of an isolated 17,20-lyase deficiency. In particular, the N177D mutant cDNA encodes a protein with 10% 17␣-hydroxylase and 17,20-lyase activities. The R496H mutant protein retains 30% 17␣-hydroxylase activity and 29% 17,20-lyase activity compared to wild type. The molecular basis of an isolated 17,20-lyase defect in a third genotypically male patient, again of Turkish ancestry, was found to be a ho- mozygote R35L missense mutation. The expressed protein retains 38% 17␣-hydroxylase and 33% 17,20-lyase activity, again in apparent contradiction to the phenotype. All data are summarized in Table 1 .
In light of the recent findings pointing to the role of phosphorylation in the regulation of 17,20-lyase activity, we investigated the phosphorylation state of our mutant proteins. Although labeled immunoprecipitable protein was seen when wild-type, N177D, R496H, R35L, and R96W enzymes were expressed in COS-1 cells, no phosphorylated protein was present when the previously characterized F417C mutant protein was expressed (Fig. 2) . The rate of phosphate incorporation in the other mutants ranged from 61-107% of that in the wild type, with no relation to the activity data, except for the F417C mutant. To explain the apparent discrepancy between the clinical picture and the genotype, we investigated the role of the physiological second messenger cAMP on activities and phosphorylation state of our 17,20-lyase-deficient mutant proteins. The addition of 8-bromocAMP induces an increase in 17␣-hydroxylase activity in all proteins tested ranging from 1.3-to 15-fold and a comparable rise in 17,20-lyase activity in wild-type, N177D, and R496H proteins (2-to 4.5-fold). The mutants F417C and R35L showed no such change in 17,20-lyase activity upon cAMP treatment (Table 2) . Consistent with that, cAMP treatment induced an increment in phosphorylated protein in the wildtype protein (Fig. 3) and all of the other mutant proteins (not shown), with no effect on the amount of immunoprecipitable F417C and R35L proteins. The changes in labeled protein are not due to an increase in protein content, as demonstrated by the comparable amounts of [
35 S]methionine-labeled proteins (Fig. 3) . The lack of response of R35L protein to the physiological effector, although not completely clear, can partly explain the phenotype-genotype discrepancy. In addition, this experiment confirms that the kinase involved in CYP17 phosphorylation is cAMP dependent, as physiologically expected.
Discussion
The study of mutations in the CYP17 gene occurring in the human population is a tool not only to better understand the molecular mechanisms of its deficiency, but also to gather further information on the structure-function relationship of this protein. The possibility of analyzing patients affected by CYP17 deficiency also provides the unique chance to obtain a model to study the influence of posttranslational modifications and cofactors on the differential regulation of the two activities of CYP17: 17␣-hydroxylase and 17,20-lyase. The two activities are differentially regulated in a tissue-and time-dependent fashion, although the physiological factors governing these phenomena are still unknown. The study of CYP17 enzymatic activity regulation is of great interest to clarify the control of gonadal steroidogenesis in health (e.g. puberty) and disease (e.g. polycystic ovary disease) and to discover the mechanism underlying the maturation of the adrenal gland (adrenarche) in children.
We identified the molecular bases of CYP17 deficiency in 
All values are expressed as steroid produced (nanograms per mL/mg protein). For 17␣-hydroxylase activity, 17OH-progesterone; for 17,20-lyase activity, DHEA.
7 patients affected by complete combined 17␣-hydroxylase/ 17,20-lyase deficiency and 3 patients suffering from an isolated 17,20-lyase defect. We identified 10 mutations, 8 of which were never previously described. The rearrangements are of different natures, ranging from deletions to insertions to single base changes, and are spread throughout the gene (Fig. 4) . The expression studies demonstrated in all complete deficiency cases that both activities were diminished to the same extent and confirmed that CYP17 enzyme must retain about one fourth of its catalytic capability to prevent the onset of mineralocorticoid-dependent hypertension. Among the isolated deficiencies, only the previously described F417C mutant could be confirmed at the molecular level. We then took advantage of these human knockouts to study the possible mechanisms of 17,20-lyase activity control. With regard to the tissue-dependent differences in 17,20-lyase activity, the abundance and interaction with the reducing agents have been shown to be crucial for CYP17 activity regulation (1, 2). Nevertheless, posttranslational modifications are a more feasible mechanism to explain the developmental activation of 17,20-lyase at adrenarche (3). We therefore investigated the phosphorylation state of our mutant proteins. Although phosphorylated CYP17 proteins were seen in all cases, no phosphorylated enzyme was present when the previously characterized F417C mutant protein was expressed. This mutant allowed us to demonstrate for the first time a connection between the electron donor system and 17,20-lyase deficiency (1). The same rearrangement now provides the first example of phosphorylation mutant among CYP17-deficient patients and confirms the important role of phosphate incorporation for 17,20-lyase activity. Moreover, our experiments demonstrate for the first time the presence of a link between the electron donor system and the phosphorylation state of the enzyme for the differential regulation of 17,20-lyase vs. 17␣-hydroxylase activity of the human CYP17 enzyme. In search of the physiological player(s) governing this process, we tested the influence of the second messenger cAMP on the enzymatic activities. Administration of cAMP stimulated both 17␣-hydroxylase and 17,20-lyase activities (4-fold) and protein phosphorylation (4-to 5-fold) in all cases, with the exception of the F417C and R35L mutant proteins that did not show any change in either 17,20-lyase or phosphorylation state under cAMP treatment. These data suggest that the kinase responsible for the phosphorylation of CYP17 is at least in part cAMP dependent. The lack of response to the physiological second messenger cAMP in some mutants might provide an explanation for the occurrence of different phenotypes and justify the discrepancy between phenotype and genotype in some cases.
A possible candidate for the developmental stimulation of 17,20-lyase is insulin-like growth factor I (IGF-I). In fact, the activation of its receptor leads to a cascade of further activation of protein Ser/Thr kinases and to an increase in intracellular protein phosphorylation, a process that appears to be crucial in 17,20-lyase stimulation (Ref . 3 and this work ). An additional link between IGF-I and adrenarche is based on the observation that serum levels of IGF-I rise and fall in a pattern simultaneous with DHEA secretion. Nevertheless, IGF-I alone does not appear to play a significant role in the differential regulation of 17,20-lyase vs. 17␣-hydroxylase activity in adrenal cells, although it augments the cAMP-stimulated increase in 17,20-lyase activity in ovarian cells (Biason-Lauber, A., unpublished data). This is in agreement with previous observations demonstrating that activation of the IGF-I receptor enhances steroidogenesis in human fetal adrenal cells exclusively in the presence of ACTH (7) . IGFs appear to modulate the ACTH signal transduction pathway at a point distal from the ACTH receptor, as the same augmentation was seen when the second messenger cAMP was used. As IGF-I exerts no differential control on the two enzymatic activities of CYP17, and ACTH does not seem to play a central physiological role in the onset of adrenarche in children (8), these two factors are probably not directly involved in the control of 17,20-lyase activity.
In conclusion, we were able to positively diagnose and collect 10 new cases of complete combined 17␣-hydroxylase/ 17,20-lyase deficiency and isolated 17,20-lyase deficiency, an otherwise rare entity. That allows us to deal with clinically and biochemically in vivo well characterized phenotypes. More importantly, the use of mutations whose clinical consequences are precisely definable provides a reliable starting point to study the mechanisms involved in the regulation of 17,20-lyase vs. 17␣-hydroxylase activity. This approach has proven to be particularly useful in the case of the 17,20-lyase-deficient F417C protein. In fact, F417C not only represents our unique example of 17,20-lyase deficiency confirmed at the molecular level and has been linked to lack of electron transfer as a possible mechanism for the 17,20-lyase defect (1), but is also the first proven case of a phosphorylation mutant among the CYP17 mutants. Using this model, we could prove for the first time the existence of a link between the electron transfer system and the phosphorylation state of the CYP17 enzyme in the control of 17,20-lyase activity. From the three-dimensional structural point of view, based on the model recently described by Auchus et al. (9) , F417 appears to be located just C-terminal to the meander peptide and, although inaccessible to solvent (and therefore probably not directly involved in redox partner binding), appears to contribute to hydrophobic interactions that help to stabilize the flap between the heme-binding domain and the meander protein. Thus, F417 may help to form an edge of the redox-binding site pocket. Although F417 is not the target of phosphorylation and is not part of any known kinase recognition site, the loss of this aromatic amino acid can cause conformational changes in the CYP17 protein, impairing the binding of a specific kinase to target Ser/Thr residues.
Furthermore, the dependency of 17,20-lyase activity and phosphorylation on cAMP can help to identify new elements responsible for the clinical phenotype when a phenotypegenotype discrepancy is apparent. An example of such an event is the R35L mutant protein. Although in basal conditions R35L protein lacks 17␣-hydroxylase and 17,20-lyase activities to a similar degree, only 17,20-lyase activity failed to respond to cAMP in the presence of the clinical picture of isolated 17,20-lyase deficiency. The implications of such findings for identification of the agent governing adrenal and gonadal androgen production are clear. The factor(s) involved in the control of androgen secretion appears to function via regulation of the phosphorylation state of CYP17 and to interact with the cAMP-dependent signal transduction pathway. Therefore, we gained some more insights into the nature of the still unknown physiological trigger of adrenarche in children and perhaps into the physiopathological mechanisms underlying androgen excess, as, for example, in functional ovarian hyperandrogenism.
